Research

Hormonal

Once-weekly subcutaneous TG103 injection (15.0–30.0 mg) produces statistically significant weight loss in overweight or obese adults without diabetes, with a safety profile characterized by mild, dose-dependent gastrointestinal adverse events.

TG103 is a once-weekly injection that helps overweight or obese adults lose about 5-7% of their body weight over 12 weeks without needing diet changes. The main side effects are mild stomach issues like nausea or diarrhea, which usually get better over time. It appears safe for people without diabetes, but you should discuss the risks and benefits with a doctor.

ModerateSupportsMEDIUM confidence
In this trial, all three doses of once-weekly TG103 were well tolerated with an acceptable safety profile. TG103 demonstrated preliminary 12-week body weight loss without lifestyle interventions, thus showing great potential for the treatment of overweight and obesity.
Diaozhu Lin et al. · BMC Medicine · 2024

Why this rating

Phase 1b study with small sample size (n=48) and short duration (12 weeks), lacking long-term efficacy data.

Source

Safety, tolerability, pharmacokinetics, and pharmacodynamics of TG103 injection in participants who are overweight or obese: a randomized, double-blind, placebo-controlled, multiple-dose phase 1b study

Diaozhu Lin et al. · BMC Medicine · 2024

DOI 10.1186/s12916-024-03394-z

rct · n=48Cited 4×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →